Full Text View
Tabular View
No Study Results Posted
Related Studies
Tezosentan in Pulmonary Arterial Hypertension
This study has been terminated.
( Due to slow recruitment, the study was prematurely discontinued )
Study NCT01077297   Information provided by Actelion

First Received on February 25, 2010.   Last Updated on July 13, 2012   History of Changes
Related Studies can be found by searching for the Conditions, Interventions, and Sponsors found in this study:
Conditions listed in this trial
Pulmonary Arterial Hypertension
Additional conditions recognized in this trial
Hypertension
Hypertension, Pulmonary
More general conditions related to this trial
Cardiovascular Diseases
Lung Diseases
Respiratory Tract Diseases
Vascular Diseases
Interventions listed in this trial
Tezosentan
Additional drug interventions recognized in this trial
Epoprostenol
Phosphodiesterase 5 Inhibitors
More general drug interventions related to this trial
Antihypertensive Agents
Cardiovascular Agents
Enzyme Inhibitors
Hematologic Agents
Molecular Mechanisms of Pharmacological Action
Pharmacologic Actions
Phosphodiesterase Inhibitors
Platelet Aggregation Inhibitors
Therapeutic Uses
Vasodilator Agents
Sponsors listed in this trial
Actelion


Contact Help Desk
Lister Hill National Center for Biomedical Communications,  U.S. National Library of Medicine,
U.S. National Institutes of Health,  U.S. Department of Health & Human Services,
USA.gov,  Copyright,  Privacy,  Accessibility,  Freedom of Information Act

U.S. National Institutes of Health U.S. National Library of Medicine U.S. Department of Health & Human Services